Midocalm, 50 mg 30 pcs.

Midocalm is a myorelaxant.

Pharmacodynamics

Myorelaxant of central action. The mechanism of action is not fully elucidated. It has membrane stabilizing, local anesthetic action, inhibits conduction of impulses in primary afferent fibers and motor neurons which leads to blocking of spinal mono- and polysynaptic reflexes. < br>

It also probably secondary inhibits mediator release by inhibiting Ca2+ entry into synapses. In the brainstem, it eliminates the facilitation of excitation conduction along the reticulospinal pathway. It enhances the peripheral blood flow independently of the CNS influence. The weak antispasmodic and adrenoblocking effect of tolperizone plays a role in the development of this effect.

Pharmacokinetics

Tolperisone is well absorbed from the gastrointestinal tract after oral administration. Cmax is reached after 0.5-1 h, bioavailability is about 20%.

Tolperisone is metabolized in the liver and kidneys. It is excreted in the urine as metabolites (more than 99%). The pharmacological activity of the metabolites is unknown.

< br>.

Indications

treatment of pathologically increased muscle tone and spasms of striated muscles resulting from organic diseases of the central nervous system (damage to the pyramidal tracts, multiple sclerosis, cerebral stroke, myelopathy, encephalomyelitis);
treatment of increased tone and muscle spasms, muscle contractures accompanying diseases of the movement organs (including spondylosis, spondyloarthrosis, cervical and lumbar syndromes, arthrosis of large joints);
rehabilitation treatment after orthopedic and traumatological operations;
as part of combination therapy of obliterating vascular diseases (obliterating atherosclerosis, diabetic angiopathy, thromboangiitis obliterans, Raynaud’s disease, diffuse scleroderma), diseases arising from a disorder of vascular innervation (acrocyanosis, intermittent angioedema);
Little’s disease (infantile cerebral palsy) and other encephalopathies accompanied by muscular dystonia.

Pharmacological effect

Mydocalm is a muscle relaxant.

Pharmacodynamics

Centrally acting muscle relaxant. The mechanism of action is not fully understood. It has a membrane-stabilizing, local anesthetic effect, inhibits the conduction of impulses in primary afferent fibers and motor neurons, which leads to blocking of spinal mono- and polysynaptic reflexes.

It also probably secondarily inhibits the release of mediators by inhibiting the entry of Ca2+ into synapses. In the brain stem, it eliminates the facilitation of excitation along the reticulospinal tract. Increases peripheral blood flow regardless of the influence of the central nervous system. The weak antispasmodic and adrenergic blocking effect of tolperisone plays a role in the development of this effect.

Pharmacokinetics

After oral administration, tolperisone is well absorbed from the gastrointestinal tract. Cmax is reached after 0.5–1 hour, bioavailability is about 20%.

Tolperisone is metabolized in the liver and kidneys. Excreted in urine in the form of metabolites (more than 99%). The pharmacological activity of the metabolites is unknown.

Special instructions

Use strictly as prescribed by your doctor to avoid complications.

Impact on the ability to drive vehicles and machinery.

No studies have been conducted, but no such information has been reported over many years of use of the drug.

Active ingredient

Tolperisone

Composition

Active ingredient:

tolperisone hydrochloride;

Excipients:

citric acid monohydrate;

colloidal silicon dioxide;

stearic acid;

talc;

MCC;

corn starch;

lactose monohydrate;

Film casing:

colloidal silicon dioxide;

titanium dioxide (E171 – 77891);

lactose monohydrate;

macrogol 6000;

hypromellose

Pregnancy

The drug Mydocalm is contraindicated during pregnancy, breastfeeding and children under 3 years of age.

Contraindications

hypersensitivity to any of the components of the drug;
myasthenia gravis.

Side Effects

drowsiness,
nausea,
dizziness
dry mouth,
constipation,
diarrhea,
pressure reduction
feeling tired
sleep disorders,
confusion.

Interaction

There are no data on interactions that limit the use of Mydocalm.

Although tolperisone has an effect on the central nervous system, it does not cause a sedative effect, so it can be used in combination with sedatives, hypnotics and drugs containing alcohol.

Does not affect the effect of alcohol on the central nervous system.

Tolperisone enhances the effect of niflumic acid; when using these drugs simultaneously, it may be necessary to reduce the dose of niflumic acid.

General anesthesia, peripheral muscle relaxants, psychotropic drugs, clonidine – enhance the effect of tolperisone.

Overdose

There have been no reports of overdose with Mydocalm.

Storage conditions

In a dry place, at a temperature of 15–30 °C

Shelf life

3 years

Manufacturer

Gedeon Richter-RUS, Russia